Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease
Inflammatory Bowel Diseases · 2023
DOI: 10.1093/ibd/izac076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Tatsuya Kawamura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan. Hauptthemen laut MEDLINE: Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of treatment for Crohn’s disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum biomarker correlated with disease activity in inflammatory bowel disease. However, studies evaluating its relationship with CD, particularly in the context of small intestinal lesions, are scarce. The aim of this study was to investigate the accuracy of LRG in assessing endoscopic activity, especially remission, in patients with CD.
Methods
Between July 2020 and March 2021, 72 patients with CD who underwent LRG testing and double-balloon endoscopy at the same time were included. Endoscopic activity was evaluated using the applied Simple Endoscopic Score for Crohn’s disease, including small intestine lesions. The relationship of LRG with clinical symptoms and endoscopic activity was assessed, and its predictive accuracy was evaluated.
Results
Leucine-rich alpha-2 glycoprotein showed a significant positive correlation with endoscopic activity (r = 0.619, P < .001), even in patients with active lesions in the small intestine (r = 0.626, P < .001). Multivariate logistic regression revealed that LRG was the only factor associated with endoscopic remission. An LRG cutoff value of 8.9 μg/mL had a sensitivity of 93.3%; specificity of 83.3%; positive predictive value of 96.6%; negative predictive value of 71.4%; accuracy of 91.7%; and area under the curve of 0.904 for the prediction of endoscopic remission.
Conclusions
Leucine-rich alpha-2 glycoprotein can be used in assessing endoscopic activity and is a reliable marker of endoscopic remission in CD patients. It can be an intermediate target in the treatment of CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
- Department of Endoscopy, Nagoya University Hospital, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
ORCID-Profile: Takeshi Yamamura
Zitieren
APA
Kawamura, T., Yamamura, T., Nakamura, M., Maeda, K., Sawada, T., Ishikawa, E., Iida, T., Mizutani, Y., Ishikawa, T., Kakushima, N., Furukawa, K., Ohno, E., Honda, T., Kawashima, H., & Ishigami, M. (2023). Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac076
Vancouver
Kawamura T, Yamamura T, Nakamura M, Maeda K, Sawada T, Ishikawa E, et al. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac076
BibTeX
@article{Kawamura2023,
author = {Kawamura, Tatsuya and Yamamura, Takeshi and Nakamura, Masanao and Maeda, Keiko and Sawada, Tsunaki and Ishikawa, Eri and Iida, Tadashi and Mizutani, Yasuyuki and Ishikawa, Takuya and Kakushima, Naomi and Furukawa, Kazuhiro and Ohno, Eizaburo and Honda, Takashi and Kawashima, Hiroki and Ishigami, Masatoshi},
title = {Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2023},
doi = {10.1093/ibd/izac076}
}
EUVIMED